EU Drug Agency Recommends Approval of First Alzheimer’s Treatment Targeting Disease Progression

The EMA has reaffirmed its support for Lecanemab, a drug shown to slightly slow early-stage Alzheimer’s, but its use will be limited to a small subset of patients.